Twelve startups present disruptive healthcare solutions at Insud Pharma’s Pitch Daytheoms2019-01-31T09:48:49+01:00January 30, 2019|Read More
Publication of the final data from the clinical trial for mAbxience bevacizumab in metastatic colorectal cancer published in The Lancet Gastroenterology & Hepatologytheoms2018-09-27T12:05:35+02:00September 27, 2018|Read More
Insud Pharma secures “very good” rating in the Profarma Programmetheoms2018-09-24T13:32:46+02:00September 24, 2018|Read More
The Autonomous University of Madrid and Insud Pharma join forces for biomedical innovationtheoms2018-09-24T17:54:32+02:00July 16, 2018|Read More
mAbxience and Amneal enter into an agreement for bevacizumab biosimilar in the United Statestheoms2018-09-24T17:54:06+02:00May 23, 2018|Read More
Biosimilars reduce healthcare costs by up to 40% and increase patient accessibility to innovative treatmentstheoms2018-05-07T15:49:40+02:00May 7, 2018|Read More
Cancer Chemotherapy and Pharmacology has published comparative data of rituximab biosimilar RTXM83R in lymphoma patientstheoms2018-03-06T13:10:49+01:00March 6, 2018|Read More